These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 21357596)

  • 1. NSCLC drug targets acquire new visibility.
    Friedrich MJ
    J Natl Cancer Inst; 2011 Mar; 103(5):366-7. PubMed ID: 21357596
    [No Abstract]   [Full Text] [Related]  

  • 2. Clairvoyance or reliable prediction of the future?
    van Zandwijk N; van de Vijver MJ
    Ann Oncol; 2007 Mar; 18(3):407-8. PubMed ID: 17322538
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeted therapy in advanced non-small-cell lung cancer.
    Gettinger S
    Semin Respir Crit Care Med; 2008 Jun; 29(3):291-301. PubMed ID: 18506667
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted therapies: Tyrosine-kinase inhibitors--new standard for NSCLC therapy.
    Saijo N
    Nat Rev Clin Oncol; 2010 Nov; 7(11):618-9. PubMed ID: 20981125
    [No Abstract]   [Full Text] [Related]  

  • 5. Mechanisms of resistance to EGFR tyrosine kinase inhibitors gefitinib/erlotinib and to ALK inhibitor crizotinib.
    Tartarone A; Lazzari C; Lerose R; Conteduca V; Improta G; Zupa A; Bulotta A; Aieta M; Gregorc V
    Lung Cancer; 2013 Sep; 81(3):328-336. PubMed ID: 23809060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term response to gefitinib and crizotinib in lung adenocarcinoma harboring both epidermal growth factor receptor mutation and EML4-ALK fusion gene.
    Chiari R; Duranti S; Ludovini V; Bellezza G; Pireddu A; Minotti V; Bennati C; Crinò L
    J Clin Oncol; 2014 Mar; 32(9):e30-2. PubMed ID: 24419120
    [No Abstract]   [Full Text] [Related]  

  • 7. Polymorphisms to predict outcome to the tyrosine kinase inhibitors gefitinib, erlotinib, sorafenib and sunitinib.
    Erdem L; Giovannetti E; Leon LG; Honeywell R; Peters GJ
    Curr Top Med Chem; 2012; 12(15):1649-59. PubMed ID: 22978339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted therapies in the treatment of advanced/metastatic NSCLC.
    Pallis AG; Serfass L; Dziadziusko R; van Meerbeeck JP; Fennell D; Lacombe D; Welch J; Gridelli C
    Eur J Cancer; 2009 Sep; 45(14):2473-87. PubMed ID: 19596191
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib.
    Kelly RJ; Rajan A; Force J; Lopez-Chavez A; Keen C; Cao L; Yu Y; Choyke P; Turkbey B; Raffeld M; Xi L; Steinberg SM; Wright JJ; Kummar S; Gutierrez M; Giaccone G
    Clin Cancer Res; 2011 Mar; 17(5):1190-9. PubMed ID: 21224376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical research of crizotinib in advanced non-small cell lung cancer].
    Zhu H; Xu X; Wang L
    Zhongguo Fei Ai Za Zhi; 2013 Jun; 16(6):321-4. PubMed ID: 23769348
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re: Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non-small cell lung cancer.
    Stewart DJ
    J Natl Cancer Inst; 2008 Mar; 100(6):445-6; author reply 446. PubMed ID: 18334712
    [No Abstract]   [Full Text] [Related]  

  • 12. Tyrosine kinase inhibition of EGFR: a successful history of targeted therapy for NSCLC since 20 years.
    Vansteenkiste J; Wauters E
    Ann Oncol; 2018 Jan; 29(suppl_1):i1-i2. PubMed ID: 29462258
    [No Abstract]   [Full Text] [Related]  

  • 13. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Dwan K; Boland A; Bates V; Vecchio F; Dundar Y; Jain P; Green JA
    Cochrane Database Syst Rev; 2016 May; (5):CD010383. PubMed ID: 27223332
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Utility of Patient-Derived Xenografts to Determine Biomarkers of Prognosis and Map Resistance Pathways in EGFR-Mutant Lung Adenocarcinoma.
    Stewart EL; Mascaux C; Pham NA; Sakashita S; Sykes J; Kim L; Yanagawa N; Allo G; Ishizawa K; Wang D; Zhu CQ; Li M; Ng C; Liu N; Pintilie M; Martin P; John T; Jurisica I; Leighl NB; Neel BG; Waddell TK; Shepherd FA; Liu G; Tsao MS
    J Clin Oncol; 2015 Aug; 33(22):2472-80. PubMed ID: 26124487
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Time for molecularly targeted maintenance therapy for non-small-cell lung cancer?
    Stinchcombe TE; Ramalingam SS
    Lancet Oncol; 2010 Jun; 11(6):500-1. PubMed ID: 20493770
    [No Abstract]   [Full Text] [Related]  

  • 17. Targeting EGFR in bilio-pancreatic and liver carcinoma.
    Fratto ME; Santini D; Vincenzi B; Silvestris N; Azzariti A; Tommasi S; Zoccoli A; Galluzzo S; Maiello E; Colucci G; Tonini G
    Front Biosci (Schol Ed); 2011 Jan; 3(1):16-22. PubMed ID: 21196353
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ALK, lung cancer, and personalized therapy: portent of the future?
    Garber K
    J Natl Cancer Inst; 2010 May; 102(10):672-5. PubMed ID: 20460631
    [No Abstract]   [Full Text] [Related]  

  • 19. Alectinib surpasses crizotinib for untreated ALK-positive NSCLC.
    Gilbert JA
    Lancet Oncol; 2017 Jul; 18(7):e377. PubMed ID: 28625556
    [No Abstract]   [Full Text] [Related]  

  • 20. Role of tyrosine kinase inhibitors in lung cancer.
    Ansari J; Palmer DH; Rea DW; Hussain SA
    Anticancer Agents Med Chem; 2009 Jun; 9(5):569-75. PubMed ID: 19519298
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.